Analysts expect that Agenus Inc. (NASDAQ:AGEN – Get Rating) will post ($0.23) earnings per share (EPS) for the current quarter, Zacks reports. Three analysts have provided estimates for Agenus’ earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.25). Agenus posted earnings of ($0.37) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 37.8%. The business is expected to issue its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Agenus will report full-year earnings of ($0.89) per share for the current fiscal year, with EPS estimates ranging from ($1.08) to ($0.79). For the next fiscal year, analysts forecast that the business will report earnings of ($0.64) per share, with EPS estimates ranging from ($0.82) to ($0.53). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Agenus.
Agenus (NASDAQ:AGEN – Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.10. The firm had revenue of $25.94 million for the quarter, compared to the consensus estimate of $17.35 million. During the same quarter in the prior year, the firm earned ($0.27) EPS.
A number of large investors have recently made changes to their positions in AGEN. U.S. Capital Wealth Advisors LLC purchased a new position in shares of Agenus during the 1st quarter valued at $25,000. Bank of Nova Scotia purchased a new position in shares of Agenus during the 1st quarter valued at $31,000. Covestor Ltd purchased a new position in shares of Agenus during the 4th quarter valued at $32,000. Acadian Asset Management LLC purchased a new position in shares of Agenus during the 4th quarter valued at $32,000. Finally, Xponance Inc. purchased a new position in shares of Agenus during the 4th quarter valued at $33,000. Hedge funds and other institutional investors own 65.88% of the company’s stock.
Shares of NASDAQ AGEN traded up $0.01 during midday trading on Thursday, hitting $1.61. 3,194,314 shares of the stock traded hands, compared to its average volume of 4,192,393. The company has a market cap of $436.30 million, a PE ratio of -16.10 and a beta of 1.27. Agenus has a one year low of $1.40 and a one year high of $6.79. The business has a 50 day moving average price of $2.00 and a two-hundred day moving average price of $2.63.
Agenus Company Profile (Get Rating)
Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
- Get a free copy of the StockNews.com research report on Agenus (AGEN)
- PVH Corp. Looks Sharp For A Major Reversal
- The Analysts Reel In Their Targets For NetApp
- Don’t Get Gamed By Gamestop
- 3 Regional Banks Investors Can Bank On
- What To Do With Lululemon (NASDAQ: LULU)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.